Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.

Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate

Broadcom

Enbridge

The markets got jittery on inflation data and dropped. If you're worried every time the market moves, maybe you need to change your approach.

Buy Alert: 3 All-Weather Bargains For When The Market Gets Scared

Amazon

Microsoft

Long-term investors stand to benefit significantly from these three stocks in a reopening economy.

The 3 Smartest Stocks to Buy in a Reopening Economy

Bristol Myers Squibb Co (NYSE: BMY) announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). New data were presented at the American College of Cardiology Annual Scientific Session, with simultaneous publication in The Lancet.

Bristol Myers Unveils More Mavacamten Data To Backup Case For Heart Drug

Pfizer

Pfizer Inc (NYSE: PFE) and Bristol Myers Squibb Co (NYSE: BMY) partnered Eliquis (apixaban) failed to show benefit over standard of care in preventing serious clinical outcomes after a transaortic valve replacement (TAVR), according to the data from a new trial called Atlantis presented at the virtual American College of Cardiology meeting. The drug was linked to an “unexplained signal” in a subset of populations with a higher rate of non-cardiovascular deaths which did not need blood thinners apart from the surgery.

Pfizer-Bristol Myers' Eliquis Flops In Post-Heart Surgery Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC21--BMS Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with oHCM at #ACC21

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology's 70th Annual Scientific Session

DraftKings

PACCAR

Skillz

Twitter

ARK Investment, the asset management firm founded by Catherine Wood (Trades, Portfolio), disclosed this week that its top five new positions during the first quarter were in Twitter Inc. ( TWTR , Financial), PACCAR Inc. ( PCAR , Financial), DraftKings Inc. ( DKNG , Financial), Bristol-Myers Squibb Co. ( BMY , Financial) and Skillz Inc. ( SKLZ , Financial).

ARK Investment's Top 5 New Buys in the 1st Quarter

An independent panel recommended the Food and Drug Administration revoke approval for Opdivo as a second option for liver cancer patients. Is Bristol Myers Squibb stock a sell?

Is BMY Stock A Sell After Panel Recommends FDA Revoke An Opdivo Approval?

Merck

These two companies should be on your radar.

2 Top Healthcare Stocks for 2021 and Beyond

Bristol-Myers Squibb Co. ( BMY , Financial) continues to face challenges associated with Covid-19 and had a strictly mediocre first quarter given the weak demand for its multiple myeloma (MM) drug Revlimid and immuno-oncology drug Opdivo.

Bristol-Myers Squibb: An Uncertain Future

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--BMS Presents New Research at ASCO & EHA 2021

Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders

Dominion Energy

Coca-Cola

AT&T

Exxon Mobil

Those who have worked in the financial arena for decades saw the potential for some big trouble this year in January when a massive spike in retail trading sent shares of video game retailer GameStop into the stratosphere in an incredible parabolic move caused by the massive short position that had been built on the company's stock.

5 Stocks to Move to Now to Avoid the Potentially Massive Correction

PFE and BMY are among the best dividend growth healthcare stocks you can find.

Pfizer Or Bristol-Myers Squibb: Which Is A Better Buy?

Salesforce

Green Thumb Industries Inc.

Patience can pay off in a big way with these moneymaking stocks.

4 Surefire Stocks to Buy With $10,000 Right Now

AbbVie

Chevron

Marsh & McLennan

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought.

Guess Which Stocks Warren Buffett Bought: 1st-Quarter Contest

Marathon Petroleum

Realty Income Corp

PepsiCo

As the aging bull market presses ahead, it is pretty easy to see there has been a big rotation out of growth and momentum stocks and into value and cyclical ones.

5 Goldman Sachs Conviction List Growth Stocks to Buy Also Pay Big Dividends

Gilead Sciences

FATE reports a wider Q1 loss on increased R&D expenses.

FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY).  The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes.

DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference

Abbott Labs

Our constant need for medical products will be a major growth driver for these healthcare giants.

2 Top Stocks to Buy and Hold for 10 Years

Going by historical performance, there is a 62% chance of a rise in BMY stock over the next month. Out of 116 instances in the last ten years that BMY stock saw a five-day decline of 5.2% or more, 72 of them resulted in BMY stock rising over the subsequent one month period.

What Bristol Myers Squibb's Q1 Results Say About Its Stock

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at upcoming ACC.21

Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology's 70th Annual Scientific Session

Investors will have to wait for the full data set to see how much the drug could really help cancer patients.

This Data Could Accelerate Bristol Myers Squibb's Cancer Drug Opportunity

The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received a price target decrease from $70 to $62. These are the details.

News for Bristol-Myers Stock (BMY)